A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells...

Area of Science:

• Oncology
• Drug Delivery
• Biochemistry

Background:

• Prostate cancer remains a leading cause of cancer-related deaths.
• Conventional chemotherapy, like doxorubicin, suffers from systemic toxicity and limited efficacy.
• Targeted drug delivery systems are crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To develop and evaluate a novel doxorubicin conjugate (L-377,202) for targeted prostate cancer therapy.
• To assess the selective cytotoxicity of L-377,202 in prostate-specific antigen (PSA)-secreting cells versus non-PSA-secreting cells.
• To determine the in vivo efficacy and therapeutic index of L-377,202 in a prostate cancer xenograft model.

Main Methods:

• Covalent linkage of doxorubicin to a PSA-hydrolyzable peptide.
• In vitro cytotoxicity assays using PSA-secreting and non-secreting cancer cell lines.
• In vivo efficacy studies in nude mice bearing human prostate cancer xenografts, comparing L-377,202 with conventional doxorubicin at maximally tolerated doses.

Main Results:

• L-377,202 demonstrated significantly lower cytotoxicity in non-PSA-secreting cells compared to conventional doxorubicin.
• L-377,202 was approximately 15 times more effective than doxorubicin in inhibiting human prostate cancer tumor growth in vivo.
• Treatment with L-377,202 led to substantial tumor burden reduction with minimal weight loss in mice.

Conclusions:

• The PSA-cleavable conjugate L-377,202 enables targeted delivery of doxorubicin to prostate tumors.
• This targeted approach significantly improves the therapeutic index of doxorubicin for prostate cancer.
• L-377,202 represents a promising strategy for enhanced prostate cancer chemotherapy with reduced systemic side effects.